SEC Comment Letter 0000000000-25-000132 to Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD.
Date: Jan. 6, 2025 · CIK: 0001962011 · Accession: 0000000000-25-000132
AI Filing Summary & Sentiment
Reasoning
Letter
January 6, 2025 John S. Yu, M.D. Chief Executive Officer Kairos Pharma, Ltd. 2355 Westwood Blvd., #139 Los Angeles CA 90064 Re:Kairos Pharma, Ltd. Draft Registration Statement on Form S-1 Submitted January 3, 2025 CIK No. 0001962011 Dear John S. Yu M.D.: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Megan J. Penick, Esq.
Show Raw Text
January 6, 2025
John S. Yu, M.D.
Chief Executive Officer
Kairos Pharma, Ltd.
2355 Westwood Blvd., #139
Los Angeles CA 90064
Re:Kairos Pharma, Ltd.
Draft Registration Statement on Form S-1
Submitted January 3, 2025
CIK No. 0001962011
Dear John S. Yu M.D.:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours
prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding
requests for acceleration. We remind you that the company and its management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Megan J. Penick, Esq.